BACKGROUND: The pathogenesis of inflammatory bowel disease (IBD) involves the role of bacteria. These bacteria ferment nonstarch polysaccharides in the colon producing a fermentation profile that through altered gut permeability can be traced in urine. We proposed to track the resultant volatile organic compounds or gases that emanate from urine using noninvasive real-time tools, specifically by electronic nose and Field Asymmetric Ion Mobility Spectrometer (FAIMS) instruments. The aim of this study was to determine the utility of electronic nose and FAIMS instruments to detect and track the fermentation profile of patients with IBD. METHODS: Sixty-two individuals were recruited, 48 individuals with IBD (24 with Crohn's disease and ulcerative colitis, respectively) and 14 controls. The disease activity was recorded, and urine samples were collected. The headspace (the air above the sample) was analyzed using the electronic nose and FAIMS instruments. RESULTS: Electronic nose data analysis was conducted through (1) Principal Component Analysis (data were analyzed together without previous categorization); and (2) Discriminant Function Analysis (samples were precategorized [clinical groups]). The FAIMS data were processed by Fisher's Discriminant Analysis (precategorized [clinical groups]). Both technologies consistently showed the ability to separate those with IBD and controls with a >75% accuracy; P < 0.001. In a smaller subgroup (n = 24), we also demonstrated that the electronic nose and FAIMS instruments can distinguish between active disease and those in remission. CONCLUSIONS: The fermentation profile or fermentome is disparate in those with IBD compared with controls--a reflection of the bacterial diversity in health and disease. This profile also changes (and was tracked) as the disease is induced into remission. Thus, the electronic nose and FAIMS instruments offer the potential of a noninvasive real-time diagnostic tool for point of care clinical use.
BACKGROUND: The pathogenesis of inflammatory bowel disease (IBD) involves the role of bacteria. These bacteria ferment nonstarch polysaccharides in the colon producing a fermentation profile that through altered gut permeability can be traced in urine. We proposed to track the resultant volatile organic compounds or gases that emanate from urine using noninvasive real-time tools, specifically by electronic nose and Field Asymmetric Ion Mobility Spectrometer (FAIMS) instruments. The aim of this study was to determine the utility of electronic nose and FAIMS instruments to detect and track the fermentation profile of patients with IBD. METHODS: Sixty-two individuals were recruited, 48 individuals with IBD (24 with Crohn's disease and ulcerative colitis, respectively) and 14 controls. The disease activity was recorded, and urine samples were collected. The headspace (the air above the sample) was analyzed using the electronic nose and FAIMS instruments. RESULTS: Electronic nose data analysis was conducted through (1) Principal Component Analysis (data were analyzed together without previous categorization); and (2) Discriminant Function Analysis (samples were precategorized [clinical groups]). The FAIMS data were processed by Fisher's Discriminant Analysis (precategorized [clinical groups]). Both technologies consistently showed the ability to separate those with IBD and controls with a >75% accuracy; P < 0.001. In a smaller subgroup (n = 24), we also demonstrated that the electronic nose and FAIMS instruments can distinguish between active disease and those in remission. CONCLUSIONS: The fermentation profile or fermentome is disparate in those with IBD compared with controls--a reflection of the bacterial diversity in health and disease. This profile also changes (and was tracked) as the disease is induced into remission. Thus, the electronic nose and FAIMS instruments offer the potential of a noninvasive real-time diagnostic tool for point of care clinical use.
Authors: N Patel; N Alkhouri; K Eng; F Cikach; L Mahajan; C Yan; D Grove; E S Rome; R Lopez; R A Dweik Journal: Aliment Pharmacol Ther Date: 2014-07-16 Impact factor: 8.171
Authors: Pranay Chakraborty; Maneeshin Y Rajapakse; Mitchell M McCartney; Nicholas J Kenyon; Cristina E Davis Journal: Anal Methods Date: 2022-09-01 Impact factor: 3.532
Authors: Evelien F de Groot; Tim G de Meij; Daniel J Berkhout; Marc P van der Schee; Nanne K de Boer Journal: World J Gastrointest Pharmacol Ther Date: 2015-11-06
Authors: James A Covington; Eric W Westenbrink; Nathalie Ouaret; Ruth Harbord; Catherine Bailey; Nicola O'Connell; James Cullis; Nigel Williams; Chuka U Nwokolo; Karna D Bardhan; Ramesh P Arasaradnam Journal: Sensors (Basel) Date: 2013-09-06 Impact factor: 3.576
Authors: Ramesh P Arasaradnam; Eric Westenbrink; Michael J McFarlane; Ruth Harbord; Samantha Chambers; Nicola O'Connell; Catherine Bailey; Chuka U Nwokolo; Karna D Bardhan; Richard Savage; James A Covington Journal: PLoS One Date: 2014-10-16 Impact factor: 3.240
Authors: Ramesh P Arasaradnam; Michael J McFarlane; Courtenay Ryan-Fisher; Erik Westenbrink; Phoebe Hodges; Paula Hodges; Matthew G Thomas; Samantha Chambers; Nicola O'Connell; Catherine Bailey; Christopher Harmston; Chuka U Nwokolo; Karna D Bardhan; James A Covington Journal: PLoS One Date: 2014-09-30 Impact factor: 3.240
Authors: Laura Capelli; Gianluigi Taverna; Alessia Bellini; Lidia Eusebio; Niccolò Buffi; Massimo Lazzeri; Giorgio Guazzoni; Giorgio Bozzini; Mauro Seveso; Alberto Mandressi; Lorenzo Tidu; Fabio Grizzi; Paolo Sardella; Giuseppe Latorre; Rodolfo Hurle; Giovanni Lughezzani; Paolo Casale; Sara Meregali; Selena Sironi Journal: Sensors (Basel) Date: 2016-10-14 Impact factor: 3.576
Authors: Siavash Esfahani; Nidhi M Sagar; Ioannis Kyrou; Ella Mozdiak; Nicola O'Connell; Chuka Nwokolo; Karna D Bardhan; Ramesh P Arasaradnam; James A Covington Journal: Biosensors (Basel) Date: 2016-01-25